Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 75

1.

Cell-Free SHOX2 DNA Methylation in Blood as a Molecular Staging Parameter for Risk Stratification in Renal Cell Carcinoma Patients: A Prospective Observational Cohort Study.

Jung M, Ellinger J, Gevensleben H, Syring I, Lüders C, de Vos L, Pützer S, Bootz F, Landsberg J, Kristiansen G, Dietrich D.

Clin Chem. 2019 Jan 9. pii: clinchem.2018.297549. doi: 10.1373/clinchem.2018.297549. [Epub ahead of print]

PMID:
30626634
2.

Slow cortical potentials neurofeedback in children with ADHD: comorbidity, self-regulation and clinical outcomes 6 months after treatment in a multicenter randomized controlled trial.

Aggensteiner PM, Brandeis D, Millenet S, Hohmann S, Ruckes C, Beuth S, Albrecht B, Schmitt G, Schermuly S, Wörz S, Gevensleben H, Freitag CM, Banaschewski T, Rothenberger A, Strehl U, Holtmann M.

Eur Child Adolesc Psychiatry. 2019 Jan 4. doi: 10.1007/s00787-018-01271-8. [Epub ahead of print]

PMID:
30610380
3.

Detailed analysis of adenosine A2a receptor (ADORA2A) and CD73 (5'-nucleotidase, ecto, NT5E) methylation and gene expression in head and neck squamous cell carcinoma patients.

Vogt TJ, Gevensleben H, Dietrich J, Kristiansen G, Bootz F, Landsberg J, Goltz D, Dietrich D.

Oncoimmunology. 2018 Apr 18;7(8):e1452579. doi: 10.1080/2162402X.2018.1452579. eCollection 2018.

PMID:
30221045
4.

CTLA4 methylation predicts response to anti-PD-1 and anti-CTLA-4 immunotherapy in melanoma patients.

Goltz D, Gevensleben H, Vogt TJ, Dietrich J, Golletz C, Bootz F, Kristiansen G, Landsberg J, Dietrich D.

JCI Insight. 2018 Jul 12;3(13). pii: 96793. doi: 10.1172/jci.insight.96793. [Epub ahead of print]

5.

Potential of quantitative SEPT9 and SHOX2 methylation in plasmatic circulating cell-free DNA as auxiliary staging parameter in colorectal cancer: a prospective observational cohort study.

Bergheim J, Semaan A, Gevensleben H, Groening S, Knoblich A, Dietrich J, Weber J, Kalff JC, Bootz F, Kristiansen G, Dietrich D.

Br J Cancer. 2018 May;118(9):1217-1228. doi: 10.1038/s41416-018-0035-8. Epub 2018 Apr 3.

PMID:
29610456
6.

Neovascular PSMA expression is a common feature in malignant neoplasms of the thyroid.

Heitkötter B, Steinestel K, Trautmann M, Grünewald I, Barth P, Gevensleben H, Bögemann M, Wardelmann E, Hartmann W, Rahbar K, Huss S.

Oncotarget. 2018 Jan 4;9(11):9867-9874. doi: 10.18632/oncotarget.23984. eCollection 2018 Feb 9.

7.

Prostate-specific membrane antigen in breast cancer: a comprehensive evaluation of expression and a case report of radionuclide therapy.

Tolkach Y, Gevensleben H, Bundschuh R, Koyun A, Huber D, Kehrer C, Hecking T, Keyver-Paik MD, Kaiser C, Ahmadzadehfar H, Essler M, Kuhn W, Kristiansen G.

Breast Cancer Res Treat. 2018 Jun;169(3):447-455. doi: 10.1007/s10549-018-4717-y. Epub 2018 Feb 17.

PMID:
29455299
8.

PD-1 (PDCD1) Promoter Methylation Is a Prognostic Factor in Patients With Diffuse Lower-Grade Gliomas Harboring Isocitrate Dehydrogenase (IDH) Mutations.

Röver LK, Gevensleben H, Dietrich J, Bootz F, Landsberg J, Goltz D, Dietrich D.

EBioMedicine. 2018 Feb;28:97-104. doi: 10.1016/j.ebiom.2018.01.016. Epub 2018 Jan 31.

9.

Comparison of quantification algorithms for circulating cell-free DNA methylation biomarkers in blood plasma from cancer patients.

de Vos L, Gevensleben H, Schröck A, Franzen A, Kristiansen G, Bootz F, Dietrich D.

Clin Epigenetics. 2017 Dec 1;9:125. doi: 10.1186/s13148-017-0425-4. eCollection 2017.

10.

Prevalence of deleterious germline variants in risk genes including BRCA1/2 in consecutive ovarian cancer patients (AGO-TR-1).

Harter P, Hauke J, Heitz F, Reuss A, Kommoss S, Marmé F, Heimbach A, Prieske K, Richters L, Burges A, Neidhardt G, de Gregorio N, El-Balat A, Hilpert F, Meier W, Kimmig R, Kast K, Sehouli J, Baumann K, Jackisch C, Park-Simon TW, Hanker L, Kröber S, Pfisterer J, Gevensleben H, Schnelzer A, Dietrich D, Neunhöffer T, Krockenberger M, Brucker SY, Nürnberg P, Thiele H, Altmüller J, Lamla J, Elser G, du Bois A, Hahnen E, Schmutzler R.

PLoS One. 2017 Oct 20;12(10):e0186043. doi: 10.1371/journal.pone.0186043. eCollection 2017.

11.

Targeting myeloid derived suppressor cells with all-trans retinoic acid is highly time-dependent in therapeutic tumor vaccination.

Heine A, Flores C, Gevensleben H, Diehl L, Heikenwalder M, Ringelhan M, Janssen KP, Nitsche U, Garbi N, Brossart P, Knolle PA, Kurts C, Höchst B.

Oncoimmunology. 2017 Jun 16;6(8):e1338995. doi: 10.1080/2162402X.2017.1338995. eCollection 2017.

12.

Clinical performance validation of PITX2 DNA methylation as prognostic biomarker in patients with head and neck squamous cell carcinoma.

Sailer V, Gevensleben H, Dietrich J, Goltz D, Kristiansen G, Bootz F, Dietrich D.

PLoS One. 2017 Jun 15;12(6):e0179412. doi: 10.1371/journal.pone.0179412. eCollection 2017.

13.

Free-Circulating Methylated DNA in Blood for Diagnosis, Staging, Prognosis, and Monitoring of Head and Neck Squamous Cell Carcinoma Patients: An Observational Prospective Cohort Study.

Schröck A, Leisse A, de Vos L, Gevensleben H, Dröge F, Franzen A, Wachendörfer M, Schröck F, Ellinger J, Teschke M, Wilhelm-Buchstab T, Landsberg J, Holdenrieder S, Hartmann G, Field JK, Bootz F, Kristiansen G, Dietrich D.

Clin Chem. 2017 Jul;63(7):1288-1296. doi: 10.1373/clinchem.2016.270207. Epub 2017 May 17.

14.

PDCD1 (PD-1) promoter methylation predicts outcome in head and neck squamous cell carcinoma patients.

Goltz D, Gevensleben H, Dietrich J, Schroeck F, de Vos L, Droege F, Kristiansen G, Schroeck A, Landsberg J, Bootz F, Dietrich D.

Oncotarget. 2017 Jun 20;8(25):41011-41020. doi: 10.18632/oncotarget.17354.

15.

Neurofeedback of Slow Cortical Potentials in Children with Attention-Deficit/Hyperactivity Disorder: A Multicenter Randomized Trial Controlling for Unspecific Effects.

Strehl U, Aggensteiner P, Wachtlin D, Brandeis D, Albrecht B, Arana M, Bach C, Banaschewski T, Bogen T, Flaig-Röhr A, Freitag CM, Fuchsenberger Y, Gest S, Gevensleben H, Herde L, Hohmann S, Legenbauer T, Marx AM, Millenet S, Pniewski B, Rothenberger A, Ruckes C, Wörz S, Holtmann M.

Front Hum Neurosci. 2017 Mar 31;11:135. doi: 10.3389/fnhum.2017.00135. eCollection 2017.

16.

PD-L1 (CD274) promoter methylation predicts survival in colorectal cancer patients.

Goltz D, Gevensleben H, Dietrich J, Dietrich D.

Oncoimmunology. 2016 Nov 10;6(1):e1257454. doi: 10.1080/2162402X.2016.1257454. eCollection 2017.

17.

PITX3 DNA methylation is an independent predictor of overall survival in patients with head and neck squamous cell carcinoma.

Sailer V, Holmes EE, Gevensleben H, Goltz D, Dröge F, Franzen A, Dietrich J, Kristiansen G, Bootz F, Schröck A, Dietrich D.

Clin Epigenetics. 2017 Feb 2;9:12. doi: 10.1186/s13148-017-0317-7. eCollection 2017.

18.

Clinicopathological and molecular features of a large cohort of gastrointestinal stromal tumors (GISTs) and review of the literature: BRAF mutations in KIT/PDGFRA wild-type GISTs are rare events.

Huss S, Pasternack H, Ihle MA, Merkelbach-Bruse S, Heitkötter B, Hartmann W, Trautmann M, Gevensleben H, Büttner R, Schildhaus HU, Wardelmann E.

Hum Pathol. 2017 Apr;62:206-214. doi: 10.1016/j.humpath.2017.01.005. Epub 2017 Feb 1. Review.

PMID:
28159677
19.

Expression of PSMA in tumor neovasculature of high grade sarcomas including synovial sarcoma, rhabdomyosarcoma, undifferentiated sarcoma and MPNST.

Heitkötter B, Trautmann M, Grünewald I, Bögemann M, Rahbar K, Gevensleben H, Wardelmann E, Hartmann W, Steinestel K, Huss S.

Oncotarget. 2017 Jan 17;8(3):4268-4276. doi: 10.18632/oncotarget.13994.

20.

Active surveillance as a therapeutic option for patients with low-risk prostate cancer according to the 2014 International Society of Urological Pathology grading system: a review.

Helpap B, Gevensleben H.

Scand J Urol. 2017 Feb;51(1):1-4. doi: 10.1080/21681805.2016.1264996. Epub 2016 Dec 14. Review.

PMID:
27967297
21.

PITX2 DNA Methylation as Biomarker for Individualized Risk Assessment of Prostate Cancer in Core Biopsies.

Uhl B, Gevensleben H, Tolkach Y, Sailer V, Majores M, Jung M, Meller S, Stein J, Ellinger J, Dietrich D, Kristiansen G.

J Mol Diagn. 2017 Jan;19(1):107-114. doi: 10.1016/j.jmoldx.2016.08.008. Epub 2016 Dec 8.

PMID:
27939865
22.

Ectopic Myoglobin Expression Is Associated with a Favourable Outcome in Head and Neck Squamous Cell Carcinoma Patients.

Meller S, VAN Ellen A, Gevensleben H, Bicker A, Hankeln T, Gorr TA, Sailer V, Dröge F, Schröck F, Bootz F, Schröck A, Perner S, Dietrich D, Kristiansen G.

Anticancer Res. 2016 Dec;36(12):6235-6241.

PMID:
27919941
23.

Promoter methylation of the immune checkpoint receptor PD-1 (PDCD1) is an independent prognostic biomarker for biochemical recurrence-free survival in prostate cancer patients following radical prostatectomy.

Goltz D, Gevensleben H, Dietrich J, Ellinger J, Landsberg J, Kristiansen G, Dietrich D.

Oncoimmunology. 2016 Sep 2;5(10):e1221555. eCollection 2016.

24.

PD-L1 (CD274) promoter methylation predicts survival in patients with acute myeloid leukemia.

Goltz D, Gevensleben H, Grünen S, Dietrich J, Kristiansen G, Landsberg J, Dietrich D.

Leukemia. 2017 Mar;31(3):738-743. doi: 10.1038/leu.2016.328. Epub 2016 Nov 14. No abstract available.

PMID:
27840427
25.

PD-L1 promoter methylation is a prognostic biomarker for biochemical recurrence-free survival in prostate cancer patients following radical prostatectomy.

Gevensleben H, Holmes EE, Goltz D, Dietrich J, Sailer V, Ellinger J, Dietrich D, Kristiansen G.

Oncotarget. 2016 Nov 29;7(48):79943-79955. doi: 10.18632/oncotarget.13161.

26.

Theta/beta neurofeedback in children with ADHD: Feasibility of a short-term setting and plasticity effects.

Van Doren J, Heinrich H, Bezold M, Reuter N, Kratz O, Horndasch S, Berking M, Ros T, Gevensleben H, Moll GH, Studer P.

Int J Psychophysiol. 2017 Feb;112:80-88. doi: 10.1016/j.ijpsycho.2016.11.004. Epub 2016 Nov 6.

PMID:
27829128
27.

DNA Methylation of PITX2 and PANCR Is Prognostic for Overall Survival in Patients with Resected Adenocarcinomas of the Biliary Tract.

Uhl B, Dietrich D, Branchi V, Semaan A, Schaefer P, Gevensleben H, Rostamzadeh B, Lingohr P, Schäfer N, Kalff JC, Kristiansen G, Matthaei H.

PLoS One. 2016 Oct 31;11(10):e0165769. doi: 10.1371/journal.pone.0165769. eCollection 2016.

28.

PITX2 and PANCR DNA methylation predicts overall survival in patients with head and neck squamous cell carcinoma.

Sailer V, Holmes EE, Gevensleben H, Goltz D, Dröge F, de Vos L, Franzen A, Schröck F, Bootz F, Kristiansen G, Schröck A, Dietrich D.

Oncotarget. 2016 Nov 15;7(46):75827-75838. doi: 10.18632/oncotarget.12417.

29.

CDO1 promoter methylation is associated with gene silencing and is a prognostic biomarker for biochemical recurrence-free survival in prostate cancer patients.

Meller S, Zipfel L, Gevensleben H, Dietrich J, Ellinger J, Majores M, Stein J, Sailer V, Jung M, Kristiansen G, Dietrich D.

Epigenetics. 2016 Dec;11(12):871-880. Epub 2016 Sep 30.

30.

Prophylactic total gastrectomy in the management of hereditary tumor syndromes.

Pantelis D, Hüneburg R, Adam R, Holzapfel S, Gevensleben H, Nattermann J, Strassburg CP, Aretz S, Kalff JC.

Int J Colorectal Dis. 2016 Dec;31(12):1825-1833. Epub 2016 Sep 28.

PMID:
27682646
31.

The emerging role of non-coding circulating RNA as a biomarker in renal cell carcinoma.

Ellinger J, Gevensleben H, Müller SC, Dietrich D.

Expert Rev Mol Diagn. 2016 Oct;16(10):1059-1065. Epub 2016 Sep 27. Review.

PMID:
27649770
32.

CXCL12 promoter methylation and PD-L1 expression as prognostic biomarkers in prostate cancer patients.

Goltz D, Holmes EE, Gevensleben H, Sailer V, Dietrich J, Jung M, Röhler M, Meller S, Ellinger J, Kristiansen G, Dietrich D.

Oncotarget. 2016 Aug 16;7(33):53309-53320. doi: 10.18632/oncotarget.10786.

33.

Mechanisms of Therapy Resistance in Patient-Derived Xenograft Models of BRCA1-Deficient Breast Cancer.

Ter Brugge P, Kristel P, van der Burg E, Boon U, de Maaker M, Lips E, Mulder L, de Ruiter J, Moutinho C, Gevensleben H, Marangoni E, Majewski I, Józwiak K, Kloosterman W, van Roosmalen M, Duran K, Hogervorst F, Turner N, Esteller M, Cuppen E, Wesseling J, Jonkers J.

J Natl Cancer Inst. 2016 Jul 5;108(11). doi: 10.1093/jnci/djw148. Print 2016 Nov.

PMID:
27381626
34.
35.

Diagnostic and prognostic value of SHOX2 and SEPT9 DNA methylation and cytology in benign, paramalignant, and malignant ascites.

Jung M, Pützer S, Gevensleben H, Meller S, Kristiansen G, Dietrich D.

Clin Epigenetics. 2016 Mar 1;8:24. doi: 10.1186/s13148-016-0192-7. eCollection 2016.

36.

Loss of the LIM-only protein Fhl2 impairs inflammatory reaction and scar formation after cardiac ischemia leading to better hemodynamic performance.

Goltz D, Hittetiya K, Gevensleben H, Kirfel J, Diehl L, Meyer R, Büttner R.

Life Sci. 2016 Apr 15;151:348-358. doi: 10.1016/j.lfs.2016.02.084. Epub 2016 Feb 24.

PMID:
26921632
37.

The induction of human myeloid derived suppressor cells through hepatic stellate cells is dose-dependently inhibited by the tyrosine kinase inhibitors nilotinib, dasatinib and sorafenib, but not sunitinib.

Heine A, Schilling J, Grünwald B, Krüger A, Gevensleben H, Held SA, Garbi N, Kurts C, Brossart P, Knolle P, Diehl L, Höchst B.

Cancer Immunol Immunother. 2016 Mar;65(3):273-82. doi: 10.1007/s00262-015-1790-5. Epub 2016 Jan 19.

PMID:
26786874
38.

The Immune Checkpoint Regulator PD-L1 Is Highly Expressed in Aggressive Primary Prostate Cancer.

Gevensleben H, Dietrich D, Golletz C, Steiner S, Jung M, Thiesler T, Majores M, Stein J, Uhl B, Müller S, Ellinger J, Stephan C, Jung K, Brossart P, Kristiansen G.

Clin Cancer Res. 2016 Apr 15;22(8):1969-77. doi: 10.1158/1078-0432.CCR-15-2042. Epub 2015 Nov 16.

39.

The Significance of Accurate Determination of Gleason Score for Therapeutic Options and Prognosis of Prostate Cancer.

Helpap B, Ringli D, Tonhauser J, Poser I, Breul J, Gevensleben H, Seifert HH.

Pathol Oncol Res. 2016 Apr;22(2):349-56. doi: 10.1007/s12253-015-0013-x. Epub 2015 Nov 12.

PMID:
26563277
40.

Pathophysiology of ADHD and associated problems-starting points for NF interventions?

Albrecht B, Uebel-von Sandersleben H, Gevensleben H, Rothenberger A.

Front Hum Neurosci. 2015 Jun 24;9:359. doi: 10.3389/fnhum.2015.00359. eCollection 2015. Review.

41.

Near-infrared spectroscopy (NIRS) neurofeedback as a treatment for children with attention deficit hyperactivity disorder (ADHD)-a pilot study.

Marx AM, Ehlis AC, Furdea A, Holtmann M, Banaschewski T, Brandeis D, Rothenberger A, Gevensleben H, Freitag CM, Fuchsenberger Y, Fallgatter AJ, Strehl U.

Front Hum Neurosci. 2015 Jan 7;8:1038. doi: 10.3389/fnhum.2014.01038. eCollection 2014.

42.

Neurofeedback of slow cortical potentials: neural mechanisms and feasibility of a placebo-controlled design in healthy adults.

Gevensleben H, Albrecht B, Lütcke H, Auer T, Dewiputri WI, Schweizer R, Moll G, Heinrich H, Rothenberger A.

Front Hum Neurosci. 2014 Dec 11;8:990. doi: 10.3389/fnhum.2014.00990. eCollection 2014.

43.

Comprehensive validation of published immunohistochemical prognostic biomarkers of prostate cancer -what has gone wrong? A blueprint for the way forward in biomarker studies.

Huber F, Montani M, Sulser T, Jaggi R, Wild P, Moch H, Gevensleben H, Schmid M, Wyder S, Kristiansen G.

Br J Cancer. 2015 Jan 6;112(1):140-8. doi: 10.1038/bjc.2014.588. Epub 2014 Nov 25.

44.

[Vancouver classification of renal tumors: Recommendations of the 2012 consensus conference of the International Society of Urological Pathology (ISUP)].

Kristiansen G, Delahunt B, Srigley JR, Lüders C, Lunkenheimer JM, Gevensleben H, Thiesler T, Montironi R, Egevad L.

Pathologe. 2015 May;36(3):310-6. doi: 10.1007/s00292-014-2030-z. German.

PMID:
25398389
45.

Neurofeedback in attention-deficit/hyperactivity disorder - different models, different ways of application.

Gevensleben H, Moll GH, Rothenberger A, Heinrich H.

Front Hum Neurosci. 2014 Oct 21;8:846. doi: 10.3389/fnhum.2014.00846. eCollection 2014.

46.

Slow cortical potential and theta/beta neurofeedback training in adults: effects on attentional processes and motor system excitability.

Studer P, Kratz O, Gevensleben H, Rothenberger A, Moll GH, Hautzinger M, Heinrich H.

Front Hum Neurosci. 2014 Jul 24;8:555. doi: 10.3389/fnhum.2014.00555. eCollection 2014.

47.

Pathological features of breast and ovarian cancers in RAD51C germline mutation carriers.

Gevensleben H, Bossung V, Meindl A, Wappenschmidt B, de Gregorio N, Osorio A, Romero A, Buettner R, Markiefka B, Schmutzler RK.

Virchows Arch. 2014 Sep;465(3):365-9. doi: 10.1007/s00428-014-1619-1. Epub 2014 Jul 4. No abstract available.

PMID:
24993905
48.

The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial.

Sandhu SK, Schelman WR, Wilding G, Moreno V, Baird RD, Miranda S, Hylands L, Riisnaes R, Forster M, Omlin A, Kreischer N, Thway K, Gevensleben H, Sun L, Loughney J, Chatterjee M, Toniatti C, Carpenter CL, Iannone R, Kaye SB, de Bono JS, Wenham RM.

Lancet Oncol. 2013 Aug;14(9):882-92. doi: 10.1016/S1470-2045(13)70240-7. Epub 2013 Jun 28.

PMID:
23810788
49.

Activated human hepatic stellate cells induce myeloid derived suppressor cells from peripheral blood monocytes in a CD44-dependent fashion.

Höchst B, Schildberg FA, Sauerborn P, Gäbel YA, Gevensleben H, Goltz D, Heukamp LC, Türler A, Ballmaier M, Gieseke F, Müller I, Kalff J, Kurts C, Knolle PA, Diehl L.

J Hepatol. 2013 Sep;59(3):528-35. doi: 10.1016/j.jhep.2013.04.033. Epub 2013 May 9.

PMID:
23665041
50.

Noninvasive detection of HER2 amplification with plasma DNA digital PCR.

Gevensleben H, Garcia-Murillas I, Graeser MK, Schiavon G, Osin P, Parton M, Smith IE, Ashworth A, Turner NC.

Clin Cancer Res. 2013 Jun 15;19(12):3276-84. doi: 10.1158/1078-0432.CCR-12-3768. Epub 2013 May 1.

Supplemental Content

Loading ...
Support Center